Nobel Prize celebrates breakthrough science behind emerging sight-restoration research
A groundbreaking technology that uses light to control nerve cells has been recognised with the 2026 Nobel Prize in Physiology or Medicine, highlighting its exciting potential for the future of sight restoration research!
Nobel Prize winners:
Karl Deisseroth, Peter Hegemann and Georg Nagel have been awarded the 2026 Nobel Prize in Physiology or Medicine for their pioneering work on optogenetics. Their discoveries have transformed scientists’ ability to understand how individual nerve cells communicate and how groups of cells control functions such as movement, memory, feelings and behaviour.
"Optogenetics has fundamentally altered our understanding of the brain. Every day brings new discoveries, helping to solve one of humanity's great mysteries: how our incredible brain works." - the Nobel Assembly.
The Nobel Prize recognises the fundamental scientific discoveries that made optogenetics possible and offers an opportunity to celebrate the science behind an important area of ongoing research in the inherited retinal disease (IRD) field. For people living with an IRD, this is another example of how seemingly niche discoveries in science can eventually open entirely new avenues for treatment.
What is optogenetics?
In the early 2000s, Peter Hegemann and Georg Nagel discovered a light-sensitive protein called channelrhodopsin in a single-celled alga. They found that when exposed to blue light, this protein opens a channel in the cell, allowing electrically charged particles to pass through and generate an electrical signal.
Karl Deisseroth and his colleagues then developed ways of introducing the gene for channelrhodopsin into nerve cells of mice. This meant that cells that would not normally respond to light could effectively be given a light-sensitive “switch”. By shining a light on these cells, researchers could turn their activity on or off and observe what happened. Rather than simply observing that a particular group of nerve cells was active during a behaviour, scientists could manipulate those cells and investigate whether they actually caused the behaviour. This marked a major breakthrough for neuroscience.
The Nobel Committee described optogenetics as providing opportunities to map the brain in ways scientists could previously only dream of.
Why does this matter to the Retina UK community?
Many inherited retinal diseases such as RP result in progressive vision loss due to the death of light-sensing photoreceptor cells. However, even though the light-sensing photoreceptors are lost, many of the other retinal cells further along in the visual pathway remain alive. Researchers have been investigating the use of optogenetics to make these surviving cells respond to light, therefore bypassing the need for photoreceptors.
Optogenetics works by using gene therapy techniques to provide cells at the back of the eye with the genetic instructions to build a light sensitive protein. These cells do not normally sense light but could potentially take over from degenerated photoreceptors. This approach will not restore full healthy vision as it is not replacing or repairing the damaged photoreceptors. However, it could provide those with advanced sight loss with some useful functional vision such as light detection.
Various research groups and biotechnology companies such as Ray Therapeutics, GenSight and Nanoscope Therapeutics are investigating this approach with different light-sensitive proteins.
To read more about optogenetics and ongoing clinical trials please visit the links below:
- Webinar: Michael Gilhooley, Optogenetics – Retina UK
- Optogenetics – Retina UK
- RTx-015: Exploring Optogenetic Gene Therapy for RP and Choroideremia – Retina UK
- Nanoscope Announces topline results from randomised phase 2B trial of MCO-010 for retinitis pigmentosa – Retina UK